The Chief AI Ethics Officer for Pharma: When to Hire vs. Advise

Why the Role Emerged Now

Three forces have converged in the past eighteen months to make AI ethics leadership a board-level question in pharma rather than an IT-level one.

The first is regulatory. On January 14, 2026, the European Medicines Agency and the U.S. Food and Drug Administration jointly published ten principles for Good AI Practice in medicine development, establishing a shared regulatory direction across the medicines lifecycle.¹ The principles emphasize a human-centric, risk-based approach and explicitly call for organizations to establish AI governance committees, standard operating procedures, and integration of AI risk into the quality management system. In parallel, the EU AI Act’s high-risk system rules take full effect in August 2026, with fines reaching €35 million or 7% of global turnover for the most serious violations,² and most diagnostic algorithms, patient monitoring systems, and clinical decision-support platforms fall automatically into the high-risk category.³

The second force is operational. AI is no longer sitting on the periphery of pharmaceutical work. It is embedded in the critical path of drug discovery, target selection, patient recruitment, safety signal detection, and manufacturing release decisions. Deloitte’s 2026 Chief Data and Analytics Officer survey of 100 C-suite executives at companies with $1B or more in revenue found that CDAOs are increasingly being asked to act as AI trailblazers and drive long-term AI value, with ethics and governance emerging as a top-tier accountability rather than a compliance afterthought.⁴

The third force is talent-market pressure. The Chief AI Officer has become the fastest-growing C-suite role of 2026, with year-over-year growth cited around 70%, and pharma has moved noticeably. Eli Lilly appointed Thomas Fuchs from Mount Sinai as its first Chief AI Officer in October 2024, with a mandate covering drug discovery, clinical trials, manufacturing, commercial activities, and internal functions.⁵ Pfizer appointed Berta Rodriguez-Hervas, previously at Stellantis, Nvidia, and Tesla, as its Chief AI and Analytics Officer.⁶ Merck has had Walid Mehanna as Chief Data and AI Officer for several years. Novartis and Sanofi have taken different structural paths, which we will return to below.

Sitting behind all of this is a more uncomfortable observation. Researchers at Santa Clara University’s Markkula Center for Applied Ethics have argued that despite the appointments described above, no pharmaceutical company has yet named an executive singularly accountable for AI-driven drug development decisions.⁷ The Chief AI Officers who have been hired are primarily strategy and operating leaders. The ethics accountability has been spread across quality, compliance, medical, and privacy in a way that would not be tolerated for any other decision of similar consequence.

That gap is what the Chief AI Ethics Officer conversation is really about.

Four Structural Models to Consider

Before evaluating any candidate structure, it helps to name the four models the board is actually choosing between. Each has been used somewhere in the industry or in adjacent industries, and each has recognizable tradeoffs.

Most pharma boards discover, once they walk through this framing, that they are already partially implementing model three by default. That is not the same as having chosen model three, and it is often not the model that survives a hard look at operating risk.

The Dedicated Hire: Job Description and Economics

The dedicated Chief AI Ethics Officer is the newest and least-benchmarked of the four models. Very few pharma companies have hired one under that exact title. The role that comes closest, and provides the best structural template, is the Director or Head of Responsible AI role now appearing at large pharmas. Novartis has advertised a Director, Responsible AI position, and a Head, AI Strategy and Governance role based in London, both with mandates covering Responsible AI framework development, model fairness, transparency, and ethical review.⁸

What the Role Owns

A Chief AI Ethics Officer at pharma scale owns five things that cannot be effectively split across other roles without loss:

• Named accountability for AI-influenced decisions in the critical path. This is the single most important line, and the one most often missing. When a model contributes to a clinical, safety, or commercial decision that goes wrong, one executive must be answerable for whether the governance around that model was fit for purpose.
• Enterprise ethical review and risk classification. Deciding which AI use cases require lightweight review, which require formal ethics committee review, and which require pause pending external consultation. Aligned with the FDA/EMA risk-based principles and EU AI Act high-risk classification.
• Model governance standards. Bias testing methodology, human-in-the-loop requirements by use case category, model card requirements, monitoring thresholds that trigger re-review, and criteria for retirement.
• External representation. The face of the company’s AI governance posture to regulators, investors, patient advocates, and the press. Companies without this role tend to have their CEO or general counsel do it under pressure, without preparation.
• Board reporting. A named quarterly reporting cadence to the board audit and risk committee on AI ethics posture, incidents, and remediation.

Sample Job Description Elements

Compensation benchmarks are difficult to fix precisely because the role is new, but the market signals are consistent. General Chief AI Officer compensation in 2026 has been reported in the $280,000 to $650,000 base range, with total comp at Fortune 500 and frontier-AI companies pushing past $1.5M once equity is included.⁹ Novartis’s Director, Responsible AI role has been posted at $168K to $312K base. A pharma CAI Ethics Officer at SVP or EVP level would sit at the higher end of both bands, likely $450K to $700K base with substantial performance and equity components, plus a team budget of $2M to $6M annually depending on scope.

When It Fits

The Fractional Advisor Model

For biotech and mid-market pharma companies where a full-time C-suite AI ethics hire would be disproportionate to the scale of the AI portfolio, the fractional model has emerged as a credible alternative. It is well established in general Chief AI Officer engagements and has begun to appear specifically in life sciences and med-tech advisory work aimed at PE-backed and mid-market companies.¹⁰

How Fractional Actually Works

The strongest fractional models are not “consulting engagements” in the traditional sense. They are structured to give the advisor the same accountability, board seat, and decision authority as a full-time officer, but with time compressed. Umbrex’s fractional CAIO playbook describes typical engagements ranging from two days per month to three days per week for a fixed monthly retainer.¹¹ Initial engagements often follow a three-phase, 90-day structure: discovery and alignment, design and operationalization, then enablement and execution.

Economics

Fractional CAIO engagements have been reported in the range of $5,000 to $30,000 per month depending on scope, seniority, and execution support, which industry sources put at approximately 20 to 40% of the all-in cost of a full-time CAIO in the $400,000 to $750,000+ annual range.¹⁰ Fractional Chief AI Ethics Officers, where they exist, sit at the higher end of that band because the specialization is narrower and the seniority is often higher.

Where Fractional Breaks Down

The model has real limits. A fractional advisor cannot lead a large internal team through the operational work of standing up model governance across dozens of use cases. A fractional advisor cannot be the singular external face of the company’s AI posture during a regulatory inspection or major incident. And a fractional advisor whose engagement scope shrinks under budget pressure risks becoming a signature line without real authority.

The Distributed Model and Its Hidden Costs

The most common structure in pharma today is the distributed model, whether by design or by default. Ethical responsibility for AI is split across the Chief Medical Officer (clinical use cases), Chief Quality Officer (GxP and manufacturing use cases), Chief Compliance Officer (commercial and legal risk), Chief Privacy Officer (patient data), and Chief Data Officer or Chief AI Officer (technical governance). Coordination happens through an AI governance council or committee.

This model has the surface virtue of using people who already exist and understand the business. Sanofi has publicly described its Responsible AI Working Committee as a cross-functional team including legal, privacy, procurement, ethics, policy, cybersecurity, and AI and data experts across the pharmaceutical value chain, with a follow-on Interim Responsible AI Governance body reviewing high-risk use cases.¹² Novartis operates a centralized AI governance model with dedicated AI leads in each function working through a gated, risk-based evaluation process.⁸

Both are credible structures. But both are also examples of pharma companies that have chosen to distribute AI ethics accountability without pretending the distribution solves the accountability problem.

The Four Pitfalls

When the Distributed Model Actually Works

Distributed accountability can succeed, but only under specific conditions. A named executive must chair the AI governance council with clear escalation authority. The council must have a full-time program office (not a part-time secretariat) capable of preparing risk classifications, tracking incidents, and drafting board materials. And there must be a mechanism for individual council members to be overridden when their function’s commercial interests conflict with an ethics call.

The External Advisory Board

The external AI advisory board is the least contested of the four models because it is almost never used in isolation. It is a complement to whichever internal structure the company chooses. But it deserves its own treatment because most boards underspecify what they want from it, and end up with a body that generates good discussion but no consequential decisions.

What Advisory Boards Do Well

External boards provide independent perspective that internal teams cannot. They review high-risk use cases with less commercial pressure. They challenge assumptions the executive team has stopped questioning. And they signal to regulators, investors, and patient communities that the organization has invited external scrutiny.

SAP is often cited as a strong dual-structure example: an external AI advisory board reviewing high-risk use cases and suggesting improvements to AI ethics policy, paired with an internal committee that operationalizes those policies day-to-day.¹⁴ The external board is not decorative; it has documented review authority for defined categories of use case, and internal escalation paths route through it.

Composition That Works in Pharma

What Advisory Boards Cannot Do

Advisory boards cannot substitute for internal accountability. Diligent has been direct on this point: boards have several structural options for AI oversight, including assigning responsibility to existing committees, forming dedicated technology committees, or creating ethics-founded advisory councils, but external boards work only when paired with clear internal ownership.¹⁵ Harvard’s Edmond and Lily Safra Center for Ethics has similarly emphasized that ethics frameworks in healthcare AI require named internal accountability alongside external review.¹⁶

Operating Cadence That Produces Decisions

Most external advisory boards fail quietly. They meet quarterly, they hear presentations, they nod, and no consequential decision is documented as flowing from their review. The boards that actually influence outcomes share a small number of operating characteristics. They review specific use cases with named model owners, not abstract policies. They have a written charter that includes the categories of use case they must review before deployment, not after. They receive materials at least 10 business days in advance, and the materials include the same technical documentation that regulators would receive. Their recommendations are logged, and the executive committee’s response, including the reasoning for any recommendation not accepted, is documented and revisited at the next meeting.

Advisory boards that produce a discussion but no traceable decision path have not failed because the members were wrong. They have failed because the operating model did not require the sponsoring executive to close the loop. Boards designing this structure should specify, in the charter, that no high-risk use case can enter production without a documented advisory board recommendation and a documented executive response.

Compensation and Term Structure

Meaningful advisory board work is not volunteer work at the seniority pharma companies need. Sitting members should be compensated at rates comparable to non-executive board directors in the range of $30,000 to $75,000 annually depending on meeting cadence and case review load, with additional per-diem for extraordinary sessions. Terms of two to three years, renewable once, keep the board fresh while maintaining institutional memory. Members should be indemnified for their advisory activity and covered by the company’s directors and officers insurance for their scope of work.

A Decision Tree You Can Use With Your Board

The following decision tree is designed to be walked through in a board or executive committee meeting. It assumes the question on the table is not whether to strengthen AI ethics governance, but which structure to choose.

What Adjacent Industries Have Learned

Pharma is not the first regulated industry to face this question. Financial services and insurance have moved faster on AI ethics governance, driven by consumer protection regulators and a longer history of model risk management. Their experience is worth internalizing.

Financial Services

The reinsurance industry has been particularly explicit. EY’s case study on Reinsurance Group of America describes an enhanced approach for testing insurance models for fairness and bias compliance, structured around independent review authority separate from the model owners.¹⁷ The core lesson is that model risk management, which financial services has operated under regulatory expectation for over a decade, is the closest analog to what pharma is now being asked to build. Pharma companies that have hired Chief Model Risk Officers from banking have moved faster than those trying to invent the discipline from scratch.

Healthcare and Payer

Deloitte’s 2026 survey of 100 health system and health plan technology executives showed that health systems are ahead of pharma in appointing formal AI leadership, driven by the operational immediacy of AI in clinical documentation, prior authorization, and revenue cycle.¹⁸ Their pain points are pharma’s leading indicators: the health systems that appointed AI leadership without giving that leader real veto authority have found themselves absorbing risk without proportionate governance.

The Epic MyChart Case

A cautionary example that has been widely cited in AI ethics board discussions: Epic’s MyChart system permitted health practitioners to select a setting allowing AI-generated communications to patients. Research revealed hallucinations in approximately 6% of communications reviewed.¹⁹ The lesson for pharma boards is not about Epic specifically. It is about how quickly a feature that seems administrative can move into patient-facing territory where the ethics posture matters, and how easily that transition can happen without any single executive noticing until after deployment.

Insurance Underwriting and the Fairness Testing Playbook

Beyond reinsurance, the broader insurance sector has built out fairness testing methodologies that pharma can adapt directly for clinical trial patient selection models, safety signal detection algorithms, and commercial targeting. The pattern is consistent. Fairness testing is conducted by a function organizationally separate from the model developers. Test datasets are curated to include protected class representation at rates that match or exceed the deployment population. Testing is performed at pre-deployment, at defined intervals post-deployment, and after any material change to the model or its input data. Findings are reported to a governance body with authority to require remediation before continued use.

Pharma boards evaluating whether to hire a dedicated Chief AI Ethics Officer should ask whether their current structure could produce these five things without heroic effort. If the honest answer is no, distributed governance is not producing the output the board would want to see if regulators asked.

The Model Risk Management Analog

The single most transferable framework from financial services to pharma is model risk management, formalized in the U.S. through the OCC and Federal Reserve’s SR 11-7 guidance. SR 11-7 established that banks must have an independent function reviewing models, with a defined model inventory, tiered review by risk classification, documented validation, ongoing monitoring, and a governance committee with authority to require remediation or retirement. Pharma is now being pushed by FDA and EMA joint principles toward a substantially similar structure for AI models used in the drug development lifecycle. The Chief AI Ethics Officer role at large pharma will look, in most respects, like the Chief Model Risk Officer role at large banks: independent reporting line, defined authority, direct access to the audit committee, and named accountability for the state of the model inventory.

The organizations that recognized this analog early have found it easier to recruit for the role, because the talent pool of experienced model risk officers with independent authority is deeper than the emerging pool of AI ethics specialists. The organizations that treated AI ethics as a purely novel discipline have struggled to fill the role at appropriate seniority.

First 90 Days: What the New Officer Should Actually Do

Assume the board has decided on a structure and the officer, whether dedicated or fractional, is starting Monday. What should the first 90 days actually produce? This is often where the strategic decision fails at the tactical level. Boards approve the hire, executive committees welcome the new leader, and six months later the officer is still writing the charter.

A Chief AI Ethics Officer who has not produced these three artifacts by day 90 is unlikely to produce them by day 270. Boards should build the artifacts into the initial performance expectation, and the officer should negotiate the resource commitment needed to deliver them before accepting the role.

Conclusion

The Chief AI Ethics Officer conversation is often framed as a hiring question. It is more usefully framed as an accountability question. The organizations that end up in a strong position are the ones where a specific executive can be named, before an incident, as the person the board will look to when something goes wrong. Whether that person is a full-time hire, a fractional advisor, or a distributed-model chair with genuine veto authority matters less than whether the person exists and knows they exist.

For most large pharmaceutical companies, our view is that the dedicated hire will become the norm within 24 to 36 months, driven by the combination of EU AI Act enforcement, FDA and EMA joint principles, and the reputational cost of the first significant AI-related regulatory finding in the industry. For biotech and mid-market pharma, the fractional model is the pragmatic answer for the next 12 to 18 months, provided the fractional advisor is empowered with the same authority a full-time officer would have. In all cases, an external advisory board is a low-cost, high-signal governance layer that should be added early rather than late.

Sakara Digital works with pharma and biotech organizations building AI governance structures that hold up to FDA, EMA, and MHRA scrutiny while remaining practical to operate. If you are weighing the choice between a dedicated Chief AI Ethics Officer, a fractional advisor, or a redesign of your distributed model, we are happy to have that conversation and share what we have seen work.